Management of Right Jaw and Lip Numbness Post-SBRT in Metastatic Breast Cancer Patient on Tagrisso
This patient's jaw and lip numbness most likely represents either radiation-induced cranial nerve injury (specifically trigeminal nerve V3 branch/inferior alveolar nerve) from SBRT to the skull base lesion, or less likely, direct tumor involvement of the mandibular foramen/mental nerve from skull bone metastasis progression. Immediate neuroimaging with contrast-enhanced MRI of the skull base and mandible is essential to differentiate between these etiologies, as management differs substantially.
Diagnostic Approach
Obtain urgent MRI of the skull base with thin cuts through the foramen ovale and mandibular foramen to assess for:
- Radiation necrosis versus tumor progression at the treated site
- Direct tumor extension into the mandibular canal or foramen ovale
- Perineural tumor spread along V3 distribution
- Leptomeningeal disease
The timing post-SBRT is critical: symptoms appearing within weeks suggest acute radiation effect or tumor progression, while onset months to years later suggests late radiation injury 1. Radiation necrosis can occur in up to 25% of cases several months to years after stereotactic irradiation 1.
Differential Diagnosis Priority
- Radiation-induced neuropathy (most common with skull base SBRT)
- Progressive skull bone metastasis with mandibular foramen involvement 2, 3
- Radiation necrosis of adjacent brain tissue affecting nerve pathways 4
- Leptomeningeal disease (less likely but must exclude)
Immediate Management
If Imaging Shows No Progression:
Symptomatic management for radiation-induced neuropathy:
- Gabapentin 300 mg TID, titrate up to 900-1800 mg/day for neuropathic pain/dysesthesia
- Alternative: Pregabalin 75 mg BID, titrate to 150-300 mg BID
- Duloxetine 30-60 mg daily if gabapentinoids insufficient
- Avoid opioids as first-line for neuropathic symptoms
Continue Tagrisso at current dose - systemic therapy should not be switched when brain/bone is the only site of progression and has been treated with local therapy 5.
If Imaging Shows Tumor Progression:
This represents local failure requiring additional local therapy:
- Re-irradiation with stereotactic radiosurgery (SRS) is reasonable if prior SBRT dose allows 6, 7
- Surgical decompression if significant mass effect on nerve structures or need for tissue diagnosis 5, 8
- Continue Tagrisso - do not switch systemic therapy for isolated CNS/bone progression after local treatment 5
Important caveat: Tagrisso (osimertinib) is FDA-approved for EGFR-mutant NSCLC, not breast cancer 9. If this patient truly has metastatic breast cancer, Tagrisso is off-label and likely ineffective. Verify the primary diagnosis immediately - this may be EGFR-mutant lung cancer mischaracterized as breast cancer, or dual primaries. If confirmed breast cancer, systemic therapy should follow HER2-positive breast cancer guidelines with appropriate HER2-directed therapy 5.
Specific Considerations for Skull Base/Bone Metastases
Skull base metastases from breast cancer commonly cause cranial neuropathies through direct bone involvement or perineural spread 10, 11. The mental nerve (V3 branch) distribution causing "numb chin syndrome" is a recognized presentation of mandibular metastases 2, 3.
Palliative radiotherapy to skull base lesions effectively improves cranial nerve symptoms within 1 week in most cases 10. Since this patient already received SBRT, symptom onset suggests either:
- Inadequate initial coverage of the involved skull base
- Progression outside the treatment field
- Radiation-induced nerve injury (paradoxical worsening)
Monitoring and Follow-up
- Serial MRI every 2-3 months to monitor for further progression 5, 6
- Neurological examination at each visit documenting extent of sensory loss
- Assess for other cranial nerve involvement (diplopia, facial weakness, hearing loss) suggesting progressive skull base disease
- Monitor for complications of Tagrisso including ILD/pneumonitis, QTc prolongation, and cardiomyopathy per FDA labeling 9
Critical Red Flags Requiring Urgent Intervention
- Progressive neurological deficits (additional cranial nerves, motor weakness)
- Severe neuropathic pain unresponsive to medications
- Signs of increased intracranial pressure (headache, vomiting, vision changes)
- Dysphagia or aspiration risk from lower cranial nerve involvement
Multidisciplinary discussion with radiation oncology, neurosurgery, and medical oncology is mandatory to determine optimal sequencing of local and systemic therapies 12. For symptomatic brain/skull metastases, local therapy should not be deferred regardless of systemic therapy used 6.